Dhamodharan Venugopal

Dr. Dhamodharan Venugopal

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2023 in Journal of the American Chemical Society
Verified
Journal Article
Open access
KFKeisuke Fukunaga
Keisuke Fukunaga
DVDhamodharan Venugopal
Dhamodharan Venugopal
NMNao Miyahira
Nao Miyahira
YNYoko Nomura
Yoko Nomura
KMKamila Mustafina
Kamila Mustafina
YYYohei Yokobayashi
Yohei Yokobayashi

12 April 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ROHAN KALYAN REJROHAN KALYAN REJ
ROHAN KALYAN REJ
SASrinivasa Rao Allu
Srinivasa Rao Allu
JRJoyeeta Roy
Joyeeta Roy
RARanjan Kumar Acharyya
Ranjan Kumar Acharyya
CNchaithanya kiran indukuru naga
chaithanya kiran indukuru naga
DVDhamodharan Venugopal
Dhamodharan Venugopal
Proteolysis-targeting chimeras (PROTACs) are an emerging therapeutic modality that show promise to open a target space not accessible to conventional small molecules via a degradation-based mechanism. PROTAC degraders, due to their bifunctional nature, which is categorized as ‘beyond the Rule of Five’, have gained attention as a distinctive therapeutic approach for oral administration in clinical settings. However, the development of PROTACs with adequate oral bioavailability remains a significant hurdle, largely due to their large size and less than ideal physical and chemical properties. This review encapsulates the latest advancements in orally delivered PROTACs that have entered clinical evaluation as well as developments highlighted in recent scholarly articles. The insights and methodologies elaborated upon in this review could be instrumental in supporting the discovery and refinement of novel PROTAC degraders aimed at the treatment of various human cancers.

14 December 2017 in Biochemistry
Verified
Journal Article
Closed access
MAMohammad Anas
Mohammad Anas
RSRicha Sharma
Richa Sharma
DVDhamodharan Venugopal
Dhamodharan Venugopal
PPP. I. Pradeepkumar
P. I. Pradeepkumar
AMAshan Manhas
Ashan Manhas
NKNiti Kumar
Niti Kumar

18 September 2019 in ACS Chemical Biology
Verified
Journal Article
Closed access
DVDhamodharan Venugopal
Dhamodharan Venugopal
PPPushpangadan Indira Pradeepkumar
Pushpangadan Indira Pradeepkumar

3 November 2017 in ACS Chemical Biology
Verified
Journal Article
Open access
DVDhamodharan Venugopal
Dhamodharan Venugopal
SKShungo Kobori
Shungo Kobori
YYYohei Yokobayashi
Yohei Yokobayashi
Deoxyribozymes are catalytic DNA sequences whose atomic structures are generally difficult to elucidate. Mutational analysis remains a principal approach for understanding and engineering deoxyribozymes with diverse catalytic activities. However, laborious preparation and biochemical characterization of individual sequences severely limit the number of mutants that can be studied biochemically. Here, we applied deep sequencing to directly measure the activities of self-hydrolyzing deoxyribozyme sequences in high throughput. First, all single and double mutants within the 15-base catalytic core of the deoxyribozyme I-R3 were assayed to unambiguously determine the tolerated and untolerated mutations at each position. Subsequently, 4096 deoxyribozyme variants with tolerated base substitutions at seven positions were kinetically assayed in parallel. We identified 533 active mutants whose first-order rate constants and activation energies were determined. The results indicate an isolated and narrow peak in the deoxyribozyme sequence space and provide a quantitative view of the effects of multiple mutations on the deoxyribozyme activity for the first time.

30 May 2018 in Chemical Communications
Verified
Journal Article
Open access
PDF file
DVDhamodharan Venugopal
Dhamodharan Venugopal
YNYoko Nomura
Yoko Nomura
MDMohammed Dwidar
Mohammed Dwidar
YYYohei Yokobayashi
Yohei Yokobayashi
Optical control of biomolecules via engineered proteins or photoactive small molecules has had a profound impact on biology. However, optochemical tools to control RNA functions in living cells are relatively limited. We synthesized a photoactivatable (photocaged) guanine to modulate gene expression under riboswitch control in both mammalian cells and Escherichia coli by light.